TCRX: TScan Therapeutics, Inc. Stock

by  •  • Comments Off on TCRX: TScan Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 126.39
Enterprise Value ($M) 23.92
Book Value ($M) 229.09
Book Value / Share 4.39
Price / Book 0.55
NCAV ($M) 155.15
NCAV / Share 2.97
Price / NCAV 0.81

Profitability (mra)
Return on Invested Capital (ROIC) -0.35
Return on Assets (ROA) -0.41
Return on Equity (ROE) -0.74

Liquidity (mrq)
Quick Ratio 9.56
Current Ratio 9.56

Balance Sheet (mrq) ($M)
Current Assets 274.08
Assets 348.03
Liabilities 118.94
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Cormorant Asset Management, LP 0.00 -100.00
11-14 13G/A K2 HealthVentures Equity Trust LLC 9.98 16.04
11-14 13G/A Lynx1 Capital Management LP 3.20 -33.32
11-14 13G/A Biotechnology Value Fund L P 9.99 14.91
11-08 13G BlackRock, Inc. 9.50 0.00
04-23 13D/A Baker Bros. Advisors Lp 6.10 1.25
02-09 13G/A Gv 2017, L.p. 2.50 0.00
02-08 13G/A Pitango HealthTech Fund I, L.P. 4.30 92.59
02-07 13G/A Adage Capital Partners Gp, L.l.c. 8.96 -2.50

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-04-10 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ T
2024-03-06 10-K Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 79,845 249,942 31.95
2025-02-03 68,096 283,748 24.00
2025-01-31 61,009 182,228 33.48
2025-01-30 36,233 133,648 27.11

(click for more detail)

Similar Companies
SUPN – Supernus Pharmaceuticals, Inc. TARA – Protara Therapeutics, Inc.
TBPH – Theravance Biopharma, Inc. TKNO – Alpha Teknova, Inc.
TLPH – Talphera, Inc.


Financial data and stock pages provided by
Fintel.io